Abivax SA (NASDAQ:ABVX)
| Market Cap | 7.86B+32.1% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -336.10M-96.4% |
| EPS | -3.69+16.6% |
| Shares Out | 73.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,151,647 |
| Open | 104.56 |
| Previous Close | 102.23 |
| Day's Range | 104.15 - 107.60 |
| 52-Week Range | 69.81 - 148.83 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 153.00(+43.00%) |
| Earnings Date | Sep 21, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ABVX
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
$ABVX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABVX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABVX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABVX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ABVX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABVX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABVX
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $50.82M |
| SCHFSchwab International Equity ETF | $18.61M |
| GVIPGoldman Sachs Hedge Industry VIP ETF | $10.71M |
| ATFVAlger 35 ETF | $6.37M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $6.37M |
| VXUSVanguard Total International Stock ETF | $3.16M |
Estimated from each fund’s disclosed top holdings × AUM
ABVX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABVX’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.